Disc Medicine (NASDAQ:IRON) CFO Sells $24,378.18 in Stock

Disc Medicine, Inc. (NASDAQ:IRON) CFO Jean Franchi sold 353 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $69.06, for a total transaction of $24,378.18. Following the completion of the transaction, the chief financial officer directly owned 70,990 shares of the company’s stock, valued at approximately $4,902,569.40. This trade represents a 0.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Disc Medicine Trading Down 1.9%

NASDAQ:IRON opened at $66.62 on Monday. Disc Medicine, Inc. has a 1 year low of $30.82 and a 1 year high of $99.50. The stock’s fifty day moving average price is $74.43 and its two-hundred day moving average price is $75.62. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.45 and a quick ratio of 23.45. The company has a market cap of $2.51 billion, a P/E ratio of -11.12 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. As a group, analysts expect that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Key Headlines Impacting Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Beat on quarterly results — Disc reported Q4 and full‑year 2025 results with EPS of ($1.62), beating consensus (($1.69)) and provided a business update; the small earnings beat is a short‑term positive signal for execution and guidance clarity. Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
• Neutral Sentiment: Analyst target lowered but rating sustained — Truist cut its price target from $114 to $83 but kept a “buy” rating, signalling continued analyst confidence in the longer‑term thesis despite reduced near‑term expectations. Truist lowers price target to $83
• Neutral Sentiment: Insider sale by CFO — CFO Jean M. Franchi sold 353 shares at ~$69; the sale is small (0.49% reduction in her holdings) and appears routine rather than a clear signal of negative private information. CFO insider sale filing
• Neutral Sentiment: Short‑interest report is inconclusive — a MarketBeat entry shows anomalous/zero short interest data for February (days‑to‑cover 0.0), so there’s no clear short‑squeeze or elevated short pressure signal from this report.
• Negative Sentiment: Restructuring after FDA response — Disc’s board approved a restructuring following an FDA response, implying a regulatory/setback event that prompted corporate changes; this raises near‑term execution and timeline uncertainty for pipeline programs. Disc Medicine Implements Restructuring Following FDA Response
• Negative Sentiment: Investor litigation alert — Pomerantz LLP announced an investigation into Disc Medicine, which can increase legal risk, potential distraction, and perceived governance concerns among investors. Pomerantz investigates Disc Medicine

Institutional Trading of Disc Medicine

A number of hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Disc Medicine by 22.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock valued at $756,000 after acquiring an additional 2,807 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Disc Medicine by 1,277.1% in the 1st quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock valued at $5,386,000 after purchasing an additional 100,620 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Disc Medicine by 3.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock valued at $4,793,000 after purchasing an additional 3,454 shares in the last quarter. CWM LLC grew its holdings in shares of Disc Medicine by 213.5% during the 2nd quarter. CWM LLC now owns 1,044 shares of the company’s stock valued at $55,000 after purchasing an additional 711 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd purchased a new position in Disc Medicine in the 2nd quarter worth $497,000. Institutional investors own 83.70% of the company’s stock.

Analyst Upgrades and Downgrades

IRON has been the subject of several analyst reports. Wedbush cut their price target on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a report on Tuesday, February 17th. Raymond James Financial reissued a “market perform” rating on shares of Disc Medicine in a research note on Thursday, January 15th. Stifel Nicolaus decreased their target price on Disc Medicine from $125.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Wells Fargo & Company lowered their price target on Disc Medicine from $109.00 to $78.00 and set an “overweight” rating on the stock in a report on Tuesday, February 17th. Finally, UBS Group reissued an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Disc Medicine has an average rating of “Moderate Buy” and an average target price of $102.00.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.